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Background: Restenosis is a fundamental weakness of percutaneous femoropopliteal angioplasty (PTA).
The potential of endovascular brachytherapy (EVBT) to reduce restenosis has been evaluated in
randomized clinical trials, but no pooled analysis has been undertaken.
Methods: A systematic review was undertaken to identify randomized controlled trials in which PTA
alone was compared to PTA plus EVBT. The Pubmed and Medline databases, American Heart Association
OASIS database and conference proceedings from the Peripheral Vascular Surgery Society and Vascular
Society of Great Britain and Ireland were searched. Eligible studies were randomised controlled trials
comparing PTA to PTA plus EVBT in human subjects with at least one clinical outcome reported
(restenosis, complications, patency). Study quality was assessed by the Jadad score. Random-effects
modeling was used to generate pooled effect size estimates.
Results: Six trials (687 patients) were identiﬁed. EVBT reduced 12-month restenosis rates (pooled odds
ratio 0.50; 95% CI 0.301e0.836; p¼ 0.008). The beneﬁt disappeared by 24 months. The short-term risk of
new lesions elsewhere in the treated artery was signiﬁcantly increased by EVBT (pooled odds ratio 8.65;
95% CI 2.176e34.391; p¼ 0.002).
Conclusions: While limited by the small sample sizes in the included trials, this analysis suggests that the
early beneﬁt of EVBT is counter-balanced by the increased risk of new lesions and the lack of medium- to
long-term reductions in restenosis risk. Based upon the best available evidence, EVBT cannot be rec-
ommended for routine clinical use.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The combination of over 30 years of clinical experience, and
repeated demonstrations of clear therapeutic beneﬁt in rando-
mised studies, has cemented the role of percutaneous transluminal
angioplasty (PTA) as ﬁrst line therapy for most patients with
peripheral arterial occlusive disease. In the short term, PTA is
economically superior to open surgery, although the beneﬁt
disappears with time as re-interventions accrue.1 PTA is plagued by
relatively high rates of early tomedium-term restenosis. Restenosis
rates of up to 50% within two years have been reported.2 Numerous
pharmacological and mechanical therapies have attempted to
reduce restenosis.3 The process of PTA causes intimal splitting,
exposing the tunica media to blood constituents. The inﬂammatory
cascade is initiated with the migration of polymorphonuclearchool, University of Limerick,
4.
ciates Ltd. Published by Elsevier Ltleukocytes and smoothmuscle cells to the injury site, generating an
excessive healing response. Gradually, this leads to neo-intimal
hyperplasia which, along with constrictive re-modeling and
elastic recoil, results in restenosis.4 Radiation causes cell cycle
arrest, preventing cell replication. The radiation source can be
external (external beam radiotherapy) or internal (endovascular
brachytherapy). Early experience in the coronary circulation was
promising.5,6 Its efﬁcacy in the femoral artery has been studied in
randomized trials, although these results have been limited by low
participant numbers.7e16 There have also been concerns regarding
safety.17 We undertook a systematic review and meta-analysis to
determine whether EVBT reduces restenosis in randomised clinical
trials comparing restenosis following PTA alone to PTA plus EVBT. In
addition, we sought to determine whether EVBT is associated with
increased complications, re-interventions or de novo stenoses.
2. Methods
The systematic review was conducted in accordance with the Preferred
Reporting Items for Systematic reviews andMeta-Analyses (PRISMA) guidelines.18 In
November 2010, the electronic abstract databases Pubmed and Medline wered. All rights reserved.
Fig. 1. PRISMA ﬂow diagram.
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restrictions were used. No limits were set on the electronic searches. Manual
searches were undertaken of the abstract archives of the Peripheral Vascular
Surgery Society spring and winter conferences (1998e2010) and the Vascular
Society of Great Britain and Ireland annual scientiﬁc meeting (2004e2010). In
addition, the American Heart Association’s OASIS abstract database was searched.
This archive contains abstracts presented at all the major American Heart Associa-
tion meetings (Sessions, International Stroke Conference, Arteriosclerosis, Throm-
bosis and Vascular Biology (ATVB), Basic Cardiovascular Sciences Annual
Conferences (BCVS), High Blood Pressure, Quality of Care and Outcomes Research).
The abstracts of potentially relevant citations were scrutinized by two assessors (DM
and SRW) to determine eligibility. Studies were eligible for inclusion in the meta-
analysis provided that they met each of the following criteria: randomized
controlled trial, conducted in human subjects, patients randomized to femo-
ropopliteal segment PTA or PTAþ EVBT, at least one clinical outcome reported
(patency rates, restenosis rates, complications). Studies conducted in animals or
studies assessing the effect of EVBTon femoropopliteal stent patency were excluded.
Eligibility criteria were deﬁned in advance of the systematic review. A formal review
protocol was not recorded.
Trial quality was assessed using the Jadad score.19 The primary outcome for the
meta-analysis was morphological (angiographic or duplex ultrasound) restenosis
within 12 months. Patients were classiﬁed as restenosis or not using the criteria
adopted by the original trial authors. The secondary outcomes for meta-analysis
were: radiological restenosis within 24 months, re-intervention required within
12 months and the development of de novo arterial stenosis in the treated limb out-
with the original angioplasty site. Potentially eligible trials were reviewed inde-
pendently by two authors (DM and AOC). In case of disagreement, the senior author
(SRW) reviewed the trial to determine eligibility. Datawere extracted from the trials
for each of the outcomes listed above and recorded in an Excel spreadsheet.
Random-effects models were used to calculate a pooled odds ratio for each outcome
measure.20 Heterogeneity was evaluated using the Cochran Q-test. This is a null
hypothesis test in which a result with a p-value <0.05 indicates the presence of
signiﬁcant heterogeneity between the included studies. Bias was assessed by visual
inspection of funnel plots and also by the calculation of the HorboldeEgger statistic.
The statistical analysis was performed using Statsdirect 2.5.7 (Statsdirect Ltd,
Altrincham, United Kingdom). The 5% level was considered signiﬁcant and all p-
values are two-sided.
Results
The results of the systematic review are summarized in Fig. 1.
The initial search identiﬁed 684 potentially relevant citations.
Examination of the abstracts reduced this to 12 reports of
randomized clinical trials of EBVT as an adjunct to peripheral
PTA.7e16,21e23 A number of these papers reported different aspects
of a single trial. Consequently, outcome data for these trials were
aggregated from the various reports as follows: outcomes from
the VARA trial were obtained from two separate papers7,8; the
Cologne trial was aggregated from two separate reports9,10; three
papers11e13 were used to aggregate outcome data from the
Vienna-2 trial; the Bern trial represents post-hoc analysis of
patients recruited from a single center to two separate trials14,15;
the Vienna-3 data were obtained from a single paper.16 Two
reports by Wyttenbach et al did not include restenosis rates.21,22
Finally, the Peripheral Artery radiation Investigational Study
(PARIS Trial) was identiﬁed from scrutiny of article bibliographies.
The results of this trial have never been formally published. A
synopsis was identiﬁed in a non-peer reviewed publication, from
which some data were abstracted.23 Details of the individual trials
are summarized in Table 1. Overall, the six individual trials
included 687 patients (343 randomized to EVBT). For clarity, the
trials are referred to by name in the results, rather than by
multiple citations for each. The relevant citations for each trial are
listed in Table 1.
Morphological restenosis at 12 months
All six trials provided data with respect to angiographic reste-
nosis at 12 months (VARA, Cologne, Vienna-2, Bern, Vienna-3,
PARIS). There was a signiﬁcant reduction in the risk of restenosis
(99/343 EVBT versus 147/344 controls; pooled odds ratio 0.50; 95%CI 0.301e0.836; p¼ 0.008) (Fig. 2). There was no evidence of
heterogeneity (Cochran’s Q 10.09; 5 d.f.; p¼ 0.07) or bias
(Egger 1.86; p¼ 0.32).
Morphological restenosis at 24 months
Data regarding angiographic restenosis at 24 months were
provided by three trials (Cologne, Bern, Vienna-3). Restenosis
occurred in 43/154 EVBT patients compared to 82/157 controls.
However, the difference was not statistically signiﬁcant (pooled
odds ratio 0.32; 95% CI 0.062e1.621; p¼ 0.17) (Fig. 3). There were
insufﬁcient eligible studies to test for bias but therewas evidence of
heterogeneity (Cochran Q 17.27; 2 d.f.; p¼ 0.0002).
Further intervention within 12 months
Re-intervention rates within 12 months were reported by four
studies (VARA, Cologne, Vienna-2, Vienna-3) (Figs. 4 and 5). Re-
interventions were required in 41/171 controls compared to 25/
166 EVBT patients. This difference was almost statistically signiﬁ-
cant (pooled odds ratio 0.53; 95% CI 0.272e1.017; p¼ 0.06). There
was no evidence of heterogeneity (Cochran’s Q 3.55; 3 d.f.; p¼ 0.31)
or bias (Egger 1.92; p¼ 0.22).
De novo stenosis elsewhere in treated artery within 12 months
The development of a new stenosis elsewhere in the irradiated
artery within the ﬁrst year, but outside the previously irradiated
zone, was reported by three trials (VARA, Cologne, Vienna-3). The
ﬁndings of the original trials are summarized in Table 2. Overall,
EVBT was associated with a signiﬁcantly greater risk of de novo
stenosis. This occurred in 16/109 EVBT versus 3/115 control patients
Table 1
Characteristics of included trials.
Trial Inclusion criteria Study
size
EVBT protocol Restenosis deﬁnition Outcomes reported Jadad score
VARA7,8 Patient with stenotic or
totally occlusive femoropopliteal
lesions 10 cm in length, producing
claudication or non-critical limb
ischaemia
60 14 Gy at predetermined
points along the angioplasty
segment using a centering
catheter and iridium-192
source
Decrease in lumen
diameter 50% or
peak systolic velocity
ratio >2.5 on duplex scan
12-Month restenosis rate 2
12-Month re-intervention
rate
De novo stenosis rate
Cologne9,10 Previously untreated
femoropopliteal lesions 5 cm
for occlusions or 8 cm for stenosis
30 14 Gy along the length
of the angioplasty
segment using a
centering catheter
and iridium-192 source
Diameter reduction
>50% in the angioplasty
segment on follow-up
digital subtraction
angiography
12-Month restenosis rate 2
12-Month re-intervention
rate
De novo stenosis rate
24-Month restenosis rate
Vienna-211e13 Femoropopliteal lesion 5 cm for
de novo stenosis or any length for
recurrent lesions producing
intermittent claudication or rest
pain without tissue loss
113 Non-centering catheter
so dose varied with
catheter position; generally
calculated as 12 Gy dose
along length of angioplasty
segment
Diameter reduction
50% on follow-up
digital substraction
angiography or peak
systolic velocity increase
140% on duplex
ultrasound
12-Month restenosis rate 3
12-Month re-intervention
rate
Bern14,15 50% De novo or recurrent
femoropopliteal lesion producing
claudication or critical limb ischaemia
147 12 Gy or 14 Gy from an
iridium-192 source
depending on trial in
which patient was enrolled
50% Diameter
reduction on follow-up
angiography interpreted
by two blinded assessors
12-Month restenosis rate 2
24-Month restenosis rate
Vienna-316 Femoropopliteal lesion 5 cm for de
novo stenosis or any length for
recurrent lesions producing intermittent
claudication or rest pain without
tissue loss
134 18 Gy from an iridium-192
source delivered along
the length of the angioplasty
site using a centering catheter
>50% Luminal diameter
narrowing on follow-up
angiography or peak
systolic velocity ratio
>2.4
12-Month restenosis rate 2
12-Month re-intervention
rate
De novo stenosis rate
24-Month restenosis rate
PARIS23 Femoropopliteal lesion 203 14 Gy from an iridium-192
source delivered to a depth
of 2 mm at the angioplasty site
Not deﬁned 12-Month restenosis rate Not assessed
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no evidence of heterogeneity (Cochran’s Q 0.02; 2 d.f.; p¼ 0.99).
Insufﬁcient trials were eligible to test for bias.Sensitivity analysis
As the PARIS trial data has never been formally published,
a sensitivity analysis of morphological restenosis at 12 months was
undertaken in which the PARIS trial data were excluded. The
apparent beneﬁt of EVBT with respect to 12-month restenosis
persisted following exclusion of the PARIS data, with a pooled odds
ratio of 0.40 (95% CI 0.27e0.59; p< 0.0001). Cochran’s Q-test
remained non-signiﬁcant, indicating an absence of heterogeneity
(Cochran’s Q 3.34; p¼ 0.50). There was no evidence of bias
(Egger¼0.86; p¼ 0.54).Fig. 2. Forest plot of morphological restenosis at 12 months.Discussion
Despite technical advances in balloon angioplasty since its
inception, restenosis remains a fundamental weakness of the
procedure. Re-stenoses occur secondary to neo-intimal hyper-
plasia, which is thought to be driven by an inﬂammatory mech-
anism triggered by balloon expansion of an atherosclerotic
plaque. Shear stress in the vessel wall causes vascular injury,
leading to release of pro-inﬂammatory cytokines and activation of
circulating monocytes.24 Inﬂammatory cells adhere to the
angioplasty site, mediated in part by E-selectin.25 Inhibition of
inﬂammation may provide the key to reducing re-stenoses.
However, brachytherapy has no demonstrable effect on a range
of inﬂammatory mediators expressed in the ﬁrst 48 h following
femoropopliteal angioplasty.26Fig. 3. Morphological restenosis within 24 months.
Fig. 4. Re-intervention rates within 12 months.
Table 2
Trials reporting de novo lesions within six months following EVBT.
Trial Assessment of
de novo stenoses
Deﬁnition of
de novo stenosis
De novo
stenosis
control
arm
De novo
stenosis
EVBT
arm
VARA7,8 Single-plane
angiography and
intravascular
ultrasound at
6 months
>50% Stenosis in
the arterial segment
immediately proximal
or immediately
distal to the treated
segment
0/33 3/27
Cologne9,10 Duplex ultrasound >30% Stenosis outside
irradiated segment
3/15 4/15
Vienna-316 Duplex ultrasound;
digital subtraction
angiography or
magnetic resonance
angiography
Peak velocity ratio
>2.4 indicating >50%
stenosis in untreated
segment
1/67 7/67
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reported an initial improvement in patency rates 12 months post-
procedure. Only three trials reported results at 24 months, by
which time the patency advantage provided by EVBT had dis-
appeared. There were insufﬁcient data regarding longer-term, 5-
year follow-up to merit a formal meta-analysis. The Vienna-2
group reported identical restenosis rates at 5 years (72.5% in both
groups).11e13 Far from preventing medium- to late-term re-
stenoses, the meta-analysis of all available data suggests that EVBT
signiﬁcantly increases the risk of de novo stenosis elsewhere in the
treated artery (pooled odds ratio 8.65; 95% CI 2.176e34.391;
p¼ 0.002).
Most of the trials eligible for meta-analysis achieved Jadad
scores of two, indicating moderate quality. The studies suffered
primarily from the inherent difﬁculty in blinding staff to the use
of EVBT. The technique is quite cumbersome, often involving
a complex transfer of a patient with femoral sheaths and cathe-
ters in situ from the interventional radiology suite to the radio-
therapy suite. Blinding of subsequent outcome assessment using
duplex or digital subtraction angiography was possible, but it was
unclear from most reports whether this had been achieved. The
individual trial arms were generally well matched in terms of co-
morbidities, medication use and lesion morphology. That said, as
can be seen in Table 1, the lesions included in the trials were
generally short (<10 cm in length). In this pattern of localised
disease, 5-year patency rates of 70% have been reported,
comparable to bypass surgery. Therefore the selection criteriaFig. 5. De novo stenosis within 6 months.employed in these trials may in some way explain the apparent
lack of beneﬁt with EVBT.
There are some further limitations. Overall, the available
sample size for this meta-analysis is small, totaling 687 patients.
Moreover, follow-up is limited, with most of the trials only
reporting follow-up to 12 or 24 months. The PARIS trial is the
single largest randomised trial of EVBT in PTA. While it has been
presented at major conferences, the results have never been
formally published following peer review. Despite considerable
efforts, we were only able to identify one non-peer reviewed
publication which provides some outcome data from the PARIS
trial.23 We were unable to obtain any further data. Thus, the
conclusions regarding complications and de novo restenosis must
be treated with some caution, as the largest trial has never pub-
lished these data. Inclusion of unpublished trials in meta-analyses
is sometimes controversial. However, published trials are more
likely to show a positive treatment effect than unpublished trials.
Thus, systematic review and meta-analyses that fail to include
relevant unpublished data risk overestimating treatment effects
and further exacerbate publication bias.27 The current analysis
reports the statistical combination of the best available data from
randomised clinical trials of EVBT in PTA. The best available
evidence suggests that EVBT confers some short-term beneﬁt, but
at the expense of increased short-term arterial damage. The short-
term damage does not appear to be offset by medium-term
beneﬁts. It appears difﬁcult to justify further studies and there-
fore, one must conclude that EVBT has little clinical utility in
patients undergoing PTA.
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